Head-to-head evidence
dapiglutide vs TG103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
dapiglutide
Developed by Zealand Pharma
NCT06758583 · Phase 1 · completed
Both groups received active dapiglutide at different concentrations with no placebo or blinding, and the study measured only drug levels in the blood rather than a clinical effect. No results have been posted.
TG103
Developed by CSPC Pharmaceutical Group
NCT05997576 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss. However, no trial results are posted, so whether the primary endpoints were met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dapiglutide's landscape · TG103's landscape